

Massimo Clementi

List of Publications by Year in Descending Order

Source: <https://exaly.com/author-pdf/5966231/massimo-clementi-publications-by-year.pdf>

Version: 2024-04-28

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

195
papers

5,258
citations

39
h-index

61
g-index

197
ext. papers

6,020
ext. citations

7.3
avg, IF

5.17
L-index

#	Paper	IF	Citations
195	Nanopore ReCappable sequencing maps SARS-CoV-2 5Qapping sites and provides new insights into the structure of sgRNAs.. <i>Nucleic Acids Research</i> , 2022 ,	20.1	2
194	Mechanisms of Hepatitis C Virus Escape from Vaccine-Relevant Neutralizing Antibodies. <i>Vaccines</i> , 2021 , 9,	5.3	2
193	Viral Respiratory Pathogens and Lung Injury. <i>Clinical Microbiology Reviews</i> , 2021 , 34,	34	20
192	Characterization of a Lineage C.36 SARS-CoV-2 Isolate with Reduced Susceptibility to Neutralization Circulating in Lombardy, Italy. <i>Viruses</i> , 2021 , 13,	6.2	3
191	Weak correlation between antibody titers and neutralizing activity in sera from SARS-CoV-2 infected subjects. <i>Journal of Medical Virology</i> , 2021 , 93, 2160-2167	19.7	29
190	A case of psoriatic arthritis triggered by SARS-CoV-2 infection. <i>Rheumatology</i> , 2021 , 60, e21-e23	3.9	26
189	Naringenin is a powerful inhibitor of SARS-CoV-2 infection in vitro. <i>Pharmacological Research</i> , 2021 , 163, 105255	10.2	42
188	Secondary infections in patients hospitalized with COVID-19: incidence and predictive factors. <i>Clinical Microbiology and Infection</i> , 2021 , 27, 451-457	9.5	110
187	Fast inactivation of SARS-CoV-2 by UV-C and ozone exposure on different materials. <i>Emerging Microbes and Infections</i> , 2021 , 10, 206-210	18.9	28
186	Is co-infecting SARS-CoV-2 patients?. <i>Brazilian Journal of Anesthesiology (Elsevier)</i> , 2021 , 71, 92-93	0.2	2
185	Circulating SARS-CoV-2 variants in Italy, October 2020-March 2021. <i>Virology Journal</i> , 2021 , 18, 168	6.1	11
184	The interferon landscape along the respiratory tract impacts the severity of COVID-19. <i>Cell</i> , 2021 , 184, 4953-4968.e16	56.2	39
183	Differential plasmacytoid dendritic cell phenotype and type I Interferon response in asymptomatic and severe COVID-19 infection. <i>PLoS Pathogens</i> , 2021 , 17, e1009878	7.6	19
182	Systemic sclerosis and the COVID-19 pandemic: World Scleroderma Foundation preliminary advice for patient management. <i>Annals of the Rheumatic Diseases</i> , 2020 , 79, 724-726	2.4	38
181	Interferon- β Inhibition of Severe Acute Respiratory Syndrome-Coronavirus 2 In Vitro When Administered After Virus Infection. <i>Journal of Infectious Diseases</i> , 2020 , 222, 722-725	7	44
180	Sex-specific Alterations in the Urinary and Tissue Microbiome in Therapy-naïve Urothelial Bladder Cancer Patients. <i>European Urology Oncology</i> , 2020 , 3, 784-788	6.7	12
179	Differential Composition of Vaginal Microbiome, but Not of Seminal Microbiome, Is Associated With Successful Intrauterine Insemination in Couples With Idiopathic Infertility: A Prospective Observational Study. <i>Open Forum Infectious Diseases</i> , 2020 , 7, ofz525	1	13

178	Detection of low-level HCV variants in DAA treated patients: comparison amongst three different NGS data analysis protocols. <i>Virology Journal</i> , 2020 , 17, 103	6.1	1
177	Combined Prophylactic and Therapeutic Use Maximizes Hydroxychloroquine Anti-SARS-CoV-2 Effects. <i>Frontiers in Microbiology</i> , 2020 , 11, 1704	5.7	12
176	Molecular Tracing of SARS-CoV-2 in Italy in the First Three Months of the Epidemic. <i>Viruses</i> , 2020 , 12,	6.2	30
175	Oral and Fecal Microbiota in Lynch Syndrome. <i>Journal of Clinical Medicine</i> , 2020 , 9,	5.1	5
174	Semen infections in men with primary infertility in the real-life setting. <i>Fertility and Sterility</i> , 2020 , 113, 1174-1182	4.8	16
173	Cell-to-Cell Spread Blocking Activity Is Extremely Limited in the Sera of Herpes Simplex Virus 1 (HSV-1)- and HSV-2-Infected Subjects. <i>Journal of Virology</i> , 2019 , 93,	6.6	8
172	Synergy evaluation of anti-Herpes Simplex Virus type 1 and 2 compounds acting on different steps of virus life cycle. <i>Antiviral Research</i> , 2018 , 151, 71-77	10.8	6
171	Adjuvant role of SeptiFast to improve the diagnosis of sepsis in a large cohort of hematological patients. <i>Bone Marrow Transplantation</i> , 2018 , 53, 410-416	4.4	9
170	Autoimmune hepatitis and occult HCV infection: A prospective single-centre clinical study. <i>Autoimmunity Reviews</i> , 2017 , 16, 323-325	13.6	6
169	Entry inhibition of HSV-1 and -2 protects mice from viral lethal challenge. <i>Antiviral Research</i> , 2017 , 143, 48-61	10.8	5
168	The Microbiome of the Prostate Tumor Microenvironment. <i>European Urology</i> , 2017 , 72, 625-631	10.2	100
167	A Biologically-validated HCV E1E2 Heterodimer Structural Model. <i>Scientific Reports</i> , 2017 , 7, 214	4.9	21
166	IL28B rs12979860 genotype as a predictor marker of progression to BKVirus Associated nephropathy, after kidney transplantation. <i>Scientific Reports</i> , 2017 , 7, 6746	4.9	4
165	Inhibition of HIV-1 Reverse Transcriptase Dimerization by Small Molecules. <i>ChemBioChem</i> , 2016 , 17, 683-88	5.8	12
164	Chimeric antigen receptor (CAR)-engineered T cells redirected against hepatitis C virus (HCV) E2 glycoprotein. <i>Gut</i> , 2016 , 65, 512-23	19.2	47
163	Rational Dosing Strategies of Colistin: What About Resistance?. <i>Clinical Infectious Diseases</i> , 2016 , 62, 1054	11.6	2
162	Novel therapeutic investigational strategies to treat severe and disseminated HSV infections suggested by a deeper understanding of in vitro virus entry processes. <i>Drug Discovery Today</i> , 2016 , 21, 682-91	8.8	11
161	HHV6 Specific T-Cells Are Predictive Biomarker of Active HHV6 Infection after Allogeneic Hematopoietic Stem Cell Transplantation: Results of a Prospective Study in 213 Patients. <i>Blood</i> , 2016 , 128, 3399-3399	2.2	

160	Divergent Trends of Anti-JCPyV Serum Reactivity and Neutralizing Activity in Multiple Sclerosis (MS) Patients during Treatment with Natalizumab. <i>Viruses</i> , 2016 , 8,	6.2	1
159	Adaptive immunity against gut microbiota enhances apoE-mediated immune regulation and reduces atherosclerosis and western-diet-related inflammation. <i>Scientific Reports</i> , 2016 , 6, 29353	4.9	19
158	Human Herpesvirus 6 Infection Following Haploidentical Transplantation: Immune Recovery and Outcome. <i>Biology of Blood and Marrow Transplantation</i> , 2016 , 22, 2250-2255	4.7	25
157	Performance of commonly used genotypic assays and comparison with phenotypic assays of HIV-1 coreceptor tropism in acutely HIV-1-infected patients. <i>Journal of Antimicrobial Chemotherapy</i> , 2015 , 70, 1391-5	5.1	9
156	Heterosubtypic protection conferred by the human monoclonal antibody PN-SIA28 against influenza A virus lethal infections in mice. <i>Antimicrobial Agents and Chemotherapy</i> , 2015 , 59, 2647-53	5.9	1
155	Virus-induced preferential antibody gene-usage and its importance in humoral autoimmunity. <i>Seminars in Immunology</i> , 2015 , 27, 138-43	10.7	9
154	Adoptive T-cell therapy in the treatment of viral and opportunistic fungal infections. <i>Future Microbiology</i> , 2015 , 10, 665-82	2.9	6
153	Kuwanon-L as a New Allosteric HIV-1 Integrase Inhibitor: Molecular Modeling and Biological Evaluation. <i>ChemBioChem</i> , 2015 , 16, 2507-12	3.8	25
152	Microbiological diagnosis of sepsis: the confounding effects of a "gold standard". <i>Methods in Molecular Biology</i> , 2015 , 1237, 1-4	1.4	5
151	Direct identification of microorganisms from positive blood cultures using the lysis-filtration technique and matrix assisted laser desorption ionization time-of-flight mass spectrometry (MALDI-TOF MS): a multicentre study. <i>New Microbiologica</i> , 2015 , 38, 245-50	1.1	14
150	An update on integrase inhibitors: new opportunities for a personalized therapy? The NEXTaim Project. <i>New Microbiologica</i> , 2015 , 38, 443-90	1.1	6
149	Epitope mapping by epitope excision, hydrogen/deuterium exchange, and peptide-panning techniques combined with in silico analysis. <i>Methods in Molecular Biology</i> , 2014 , 1131, 427-46	1.4	7
148	2-Aminothiazolones as anti-HIV agents that act as gp120-CD4 inhibitors. <i>Antimicrobial Agents and Chemotherapy</i> , 2014 , 58, 3043-52	5.9	11
147	HCV E2 core structures and mAbs: something is still missing. <i>Drug Discovery Today</i> , 2014 , 19, 1964-70	8.8	24
146	Cloning of the first human anti-JCPyV/VP1 neutralizing monoclonal antibody: epitope definition and implications in risk stratification of patients under natalizumab therapy. <i>Antiviral Research</i> , 2014 , 108, 94-103	10.8	11
145	Potential impact of a microarray-based nucleic acid assay for rapid detection of Gram-negative bacteria and resistance markers in positive blood cultures. <i>Journal of Clinical Microbiology</i> , 2014 , 52, 1242-5	9.7	57
144	Cost-effectiveness of blood culture and a multiplex real-time PCR in hematological patients with suspected sepsis: an observational propensity score-matched study. <i>Expert Review of Molecular Diagnostics</i> , 2014 , 14, 623-32	3.8	6
143	Acute respiratory distress in a neutropenic febrile patient after hematopoietic cell transplantation. <i>Journal of Clinical Virology</i> , 2013 , 57, 1-4	14.5	2

142	Characterization of epitopes recognized by monoclonal antibodies: experimental approaches supported by freely accessible bioinformatic tools. <i>Drug Discovery Today</i> , 2013 , 18, 464-71	8.8	29
141	Infection and coinfection of human rhinovirus C in stem cell transplant recipients. <i>Clinical and Developmental Immunology</i> , 2013 , 2013, 236081		2
140	Comparative evaluation of the Bruker Biotyper and Vitek MS matrix-assisted laser desorption ionization-time of flight (MALDI-TOF) mass spectrometry systems for identification of yeasts of medical importance. <i>Journal of Clinical Microbiology</i> , 2013 , 51, 2453-7	9.7	72
139	A closer look at prion strains: characterization and important implications. <i>Prion</i> , 2013 , 7, 99-108	2.3	25
138	Possible future monoclonal antibody (mAb)-based therapy against arbovirus infections. <i>BioMed Research International</i> , 2013 , 2013, 838491	3	13
137	Risks of "blind" automated identification systems in medical microbiology. <i>Journal of Clinical Microbiology</i> , 2013 , 51, 3911	9.7	3
136	In vitro phenotypes to elvitegravir and dolutegravir in primary macrophages and lymphocytes of clonal recombinant viral variants selected in patients failing raltegravir. <i>Journal of Antimicrobial Chemotherapy</i> , 2013 , 68, 2525-32	5.1	27
135	Structural and antigenic definition of hepatitis C virus E2 glycoprotein epitopes targeted by monoclonal antibodies. <i>Clinical and Developmental Immunology</i> , 2013 , 2013, 450963		37
134	JC polyomavirus (JCV) and monoclonal antibodies: friends or potential foes?. <i>Clinical and Developmental Immunology</i> , 2013 , 2013, 967581		13
133	Epidemiological, molecular and clinical features of enterovirus 109 infection in children and in adult stem cell transplant recipients. <i>Virology Journal</i> , 2012 , 9, 183	6.1	5
132	Anti-hepatitis C virus E2 (HCV/E2) glycoprotein monoclonal antibodies and neutralization interference. <i>Antiviral Research</i> , 2012 , 96, 82-9	10.8	23
131	Phage display-based strategies for cloning and optimization of monoclonal antibodies directed against human pathogens. <i>International Journal of Molecular Sciences</i> , 2012 , 13, 8273-92	6.3	34
130	Neutralization interfering antibodies: a "novel" example of humoral immune dysfunction facilitating viral escape?. <i>Viruses</i> , 2012 , 4, 1731-52	6.2	22
129	The role of infections and coinfections with newly identified and emerging respiratory viruses in children. <i>Virology Journal</i> , 2012 , 9, 247	6.1	82
128	Cross-reacting antibacterial auto-antibodies are produced within coronary atherosclerotic plaques of acute coronary syndrome patients. <i>PLoS ONE</i> , 2012 , 7, e42283	3.7	16
127	Influenza B-cells protective epitope characterization: a passkey for the rational design of new broad-range anti-influenza vaccines. <i>Viruses</i> , 2012 , 4, 3090-108	6.2	8
126	HCV proteins and immunoglobulin variable gene (IgV) subfamilies in HCV-induced type II mixed cryoglobulinemia: a concurrent pathogenetic role. <i>Clinical and Developmental Immunology</i> , 2012 , 2012, 705013		14
125	Molecular signatures of hepatitis C virus (HCV)-induced type II mixed cryoglobulinemia (MCII). <i>Viruses</i> , 2012 , 4, 2924-44	6.2	12

124	Potential role of the detection of enterobacterial DNA in blood for the management of neonatal necrotizing enterocolitis. <i>Journal of Medical Microbiology</i> , 2012 , 61, 1465-1472	3.2	8
123	Residual viraemia does not influence 1 year virological rebound in HIV-infected patients with HIV RNA persistently below 50 copies/mL. <i>Journal of Antimicrobial Chemotherapy</i> , 2012 , 67, 213-7	5.1	26
122	A non-VH1-69 heterosubtypic neutralizing human monoclonal antibody protects mice against H1N1 and H5N1 viruses. <i>PLoS ONE</i> , 2012 , 7, e34415	3.7	44
121	A phage display vector optimized for the generation of human antibody combinatorial libraries and the molecular cloning of monoclonal antibody fragments. <i>New Microbiologica</i> , 2012 , 35, 289-94	1.1	18
120	New therapeutic options for HCV infection in the monoclonal antibody era. <i>New Microbiologica</i> , 2012 , 35, 387-97	1.1	15
119	Neutralization activity and kinetics of two broad-range human monoclonal IgG1 derived from recombinant Fab fragments and directed against Hepatitis C virus E2 glycoprotein. <i>New Microbiologica</i> , 2012 , 35, 475-9	1.1	8
118	Multicenter comparative study of Epstein-Barr virus DNA quantification for virological monitoring in transplanted patients. <i>Journal of Clinical Virology</i> , 2011 , 50, 224-9	14.5	25
117	Identification and structural characterization of novel genetic elements in the HIV-1 V3 loop regulating coreceptor usage. <i>Antiviral Therapy</i> , 2011 , 16, 1035-45	1.6	20
116	The new and less toxic protease inhibitor saquinavir-NO maintains anti-HIV-1 properties in vitro indistinguishable from those of the parental compound saquinavir. <i>Antiviral Research</i> , 2011 , 91, 292-5	10.8	8
115	A potential role for monoclonal antibodies in prophylactic and therapeutic treatment of influenza. <i>Antiviral Research</i> , 2011 , 92, 15-26	10.8	32
114	Pandemic 2009 H1N1 influenza virus is resistant to the antiviral activity of several interferon alpha subtypes. <i>Journal of Interferon and Cytokine Research</i> , 2011 , 31, 475-9	3.5	7
113	Cross-resistance profile of the novel integrase inhibitor Dolutegravir (S/GSK1349572) using clonal viral variants selected in patients failing raltegravir. <i>Journal of Infectious Diseases</i> , 2011 , 204, 1811-5	7	87
112	Integrase and fusion inhibitors transmitted drug resistance in naive patients with recent diagnosis of HIV-1 infection. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2011 , 56, e51-4	3.1	12
111	A human monoclonal antibody with neutralizing activity against highly divergent influenza subtypes. <i>PLoS ONE</i> , 2011 , 6, e28001	3.7	44
110	Genotypic/phenotypic patterns of HIV-1 integrase resistance to raltegravir. <i>Journal of Antimicrobial Chemotherapy</i> , 2010 , 65, 425-33	5.1	48
109	Fatal vancomycin- and linezolid-resistant <i>Enterococcus faecium</i> sepsis in a child undergoing allogeneic haematopoietic stem cell transplantation for beta-thalassaemia major. <i>Journal of Medical Microbiology</i> , 2010 , 59, 839-842	3.2	8
108	The era of molecular and other non-culture-based methods in diagnosis of sepsis. <i>Clinical Microbiology Reviews</i> , 2010 , 23, 235-51	34	267
107	Intracytoplasmic stable expression of IgG1 antibody targeting NS3 helicase inhibits replication of highly efficient hepatitis C Virus 2a clone. <i>Virology Journal</i> , 2010 , 7, 118	6.1	13

106	Monoclonal antibodies isolated from human B cells neutralize a broad range of H1 subtype influenza A viruses including swine-origin Influenza virus (S-OIV). <i>Virology</i> , 2010 , 399, 144-152	3.6	38
105	Molecular epidemiology of KI and WU polyomaviruses in infants with acute respiratory disease and in adult hematopoietic stem cell transplant recipients. <i>Journal of Medical Virology</i> , 2010 , 82, 153-6	19.7	26
104	Performance of genotypic tropism testing in clinical practice using the enhanced sensitivity version of Trofile as reference assay: results from the OSCAR Study Group. <i>New Microbiologica</i> , 2010 , 33, 195-206 ¹	1.1	35
103	Hepatitis C virus (HCV) infection may elicit neutralizing antibodies targeting epitopes conserved in all viral genotypes. <i>PLoS ONE</i> , 2009 , 4, e8254	3.7	56
102	Antigen-driven evolution of B lymphocytes in coronary atherosclerotic plaques. <i>Journal of Immunology</i> , 2009 , 183, 2537-44	5.3	23
101	Molecular diagnosis of polymicrobial sepsis. <i>Journal of Clinical Microbiology</i> , 2009 , 47, 1274-5	9.7	23
100	Survival of HIV-1 infected multidrug-resistant patients recycling enfuvirtide after a previous failure. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2009 , 51, 179-84	3.1	4
99	Dynamic features of the selective pressure on the human immunodeficiency virus type 1 (HIV-1) gp120 CD4-binding site in a group of long term non progressor (LTNP) subjects. <i>Retrovirology</i> , 2009 , 6, 4	3.6	15
98	Pregnancy and H1N1 infection. <i>Lancet, The</i> , 2009 , 374, 1417; author reply 1417-8	4.0	10
97	Dynamic patterns of human immunodeficiency virus type 1 integrase gene evolution in patients failing raltegravir-based salvage therapies. <i>Aids</i> , 2009 , 23, 455-60	3.5	63
96	Molecular cloning of the first human monoclonal antibodies neutralizing with high potency swine-origin influenza A pandemic virus (S-OIV). <i>New Microbiologica</i> , 2009 , 32, 319-24	1.1	22
95	Molecular epidemiology and pathogenic potential of underdiagnosed human papillomavirus types. <i>BMC Microbiology</i> , 2008 , 8, 112	4.5	20
94	Hepatitis C virus (HCV)-driven stimulation of subfamily-restricted natural IgM antibodies in mixed cryoglobulinemia. <i>Autoimmunity Reviews</i> , 2008 , 7, 468-72	13.6	30
93	Perspectives for the utilization of neutralizing human monoclonal antibodies as anti-HCV drugs. <i>Journal of Hepatology</i> , 2008 , 49, 299-300	13.4	25
92	Identification of a broadly cross-reacting and neutralizing human monoclonal antibody directed against the hepatitis C virus E2 protein. <i>Journal of Virology</i> , 2008 , 82, 1047-52	6.6	110
91	Persistent replication of severe acute respiratory syndrome coronavirus in human tubular kidney cells selects for adaptive mutations in the membrane protein. <i>Journal of Virology</i> , 2008 , 82, 5137-44	6.6	44
90	Molecular diagnosis of sepsis in neutropenic patients with haematological malignancies. <i>Journal of Medical Microbiology</i> , 2008 , 57, 601-604	3.2	122
89	HIV-1 replication capacity and genotype HIVs changes in patients undergoing treatment interruption or lamivudine monotherapy. <i>Journal of Medical Virology</i> , 2008 , 80, 201-8	19.7	13

88	Two-year prospective study of single infections and co-infections by respiratory syncytial virus and viruses identified recently in infants with acute respiratory disease. <i>Journal of Medical Virology</i> , 2008 , 80, 716-23	19.7	117
87	Anti-HIV-1 response elicited in rabbits by anti-idiotypic monoclonal antibodies mimicking the CD4-binding site. <i>PLoS ONE</i> , 2008 , 3, e3423	3.7	19
86	Is reduction of viral fitness a valid antiviral approach?. <i>Drug Discovery Today: Therapeutic Strategies</i> , 2007 , 4, 267-272		
85	Molecular and cellular determinants of cell-to-cell transmission of HCV in vitro. <i>Journal of Medical Virology</i> , 2007 , 79, 1491-9	19.7	12
84	The synergistic interaction of interferon types I and II leads to marked reduction in severe acute respiratory syndrome-associated coronavirus replication and increase in the expression of mRNAs for interferon-induced proteins. <i>Intervirology</i> , 2007 , 50, 156-60	2.5	13
83	Human papillomavirus infections: new perspectives for prevention and treatment. <i>New Microbiologica</i> , 2007 , 30, 189-212	1.1	5
82	Long-term study on symptomless human metapneumovirus infection in hematopoietic stem cell transplant recipients. <i>New Microbiologica</i> , 2007 , 30, 255-8	1.1	16
81	Development and validation of a molecular method for the diagnosis of medically important fungal infections. <i>New Microbiologica</i> , 2007 , 30, 308-12	1.1	16
80	Transmission in vitro of hepatitis C virus from persistently infected human B-cells to hepatoma cells by cell-to-cell contact. <i>Journal of Medical Virology</i> , 2006 , 78, 192-201	19.7	29
79	Modulation of epitope-specific anti-hepatitis C virus E2 (anti-HCV/E2) antibodies by anti-viral treatment. <i>Journal of Medical Virology</i> , 2006 , 78, 1304-11	19.7	8
78	Rapid molecular identification of fungal pathogens in corneal samples from suspected keratomycosis cases. <i>Journal of Medical Microbiology</i> , 2006 , 55, 1505-1509	3.2	17
77	Persistent symptomless human metapneumovirus infection in hematopoietic stem cell transplant recipients. <i>Journal of Infectious Diseases</i> , 2006 , 194, 474-8	7	77
76	Quantitation of <i>Bacillus clausii</i> in biological samples by real-time polymerase chain reaction. <i>Journal of Microbiological Methods</i> , 2006 , 65, 632-6	2.8	2
75	Cloning and molecular characterization of a human recombinant IgG Fab binding to the Tat protein of human immunodeficiency virus type 1 (HIV-1) derived from the repertoire of a seronegative patient. <i>Molecular Immunology</i> , 2006 , 43, 1363-9	4.3	3
74	Lamivudine monotherapy in HIV-1-infected patients harbouring a lamivudine-resistant virus: a randomized pilot study (E-184V study). <i>Aids</i> , 2006 , 20, 795-803	3.5	117
73	Redistribution of human immunodeficiency virus type 1 variants resistant to protease inhibitors after a protease inhibitor-sparing regimen. <i>AIDS Research and Human Retroviruses</i> , 2005 , 21, 545-54	1.6	4
72	Molecular mycological diagnosis and correct antimycotic treatments. <i>Journal of Clinical Microbiology</i> , 2005 , 43, 3584; author reply 3584-5	9.7	6
71	Direct sequencing of <i>Scedosporium apiospermum</i> DNA in the diagnosis of a case of keratitis. <i>Journal of Medical Microbiology</i> , 2005 , 54, 897-900	3.2	13

70	Coronaviridae and SARS-associated coronavirus strain HSR1. <i>Emerging Infectious Diseases</i> , 2004 , 10, 413-8	8.2	98
69	Genotype and phenotype patterns of human immunodeficiency virus type 1 resistance to enfuvirtide during long-term treatment. <i>Antimicrobial Agents and Chemotherapy</i> , 2004 , 48, 3253-9	5.9	74
68	Impact of a treatment including tenofovir plus didanosine on the selection of the 65R mutation in highly drug-experienced HIV-infected patients. <i>Aids</i> , 2004 , 18, 2205-8	3.5	5
67	Genotypic and phenotypic correlates of the HIV Type 1 env gene evolution in infected children with discordant response to antiretroviral therapy. <i>AIDS Research and Human Retroviruses</i> , 2004 , 20, 1306-13	1.6	11
66	Cross-reactive pseudovirus-neutralizing anti-envelope antibodies coexist with antibodies devoid of such activity in persistent hepatitis C virus infection. <i>Virology</i> , 2004 , 327, 242-8	3.6	27
65	Inhibition of hepatitis C virus nonstructural protein, helicase activity, and viral replication by a recombinant human antibody clone. <i>American Journal of Pathology</i> , 2004 , 165, 1163-73	5.8	23
64	Increased sensitivity of SARS-coronavirus to a combination of human type I and type II interferons. <i>Antiviral Therapy</i> , 2004 , 9, 1003-11	1.6	44
63	Increased Sensitivity of Sars-Coronavirus to a Combination of Human Type I and Type II Interferons. <i>Antiviral Therapy</i> , 2004 , 9, 1003-1011	1.6	53
62	Processivity and drug-dependence of HIV-1 protease. <i>Aids</i> , 2003 , 17, 663-671	3.5	24
61	Analysis of the functional relationship between V3 loop and gp120 context with regard to human immunodeficiency virus coreceptor usage using naturally selected sequences and different viral backbones. <i>Virology</i> , 2003 , 307, 328-40	3.6	15
60	Treatment of SARS with human interferons. <i>Lancet, The</i> , 2003 , 362, 1158; author reply 1158-9	4.0	9
59	Antimicrobial activity of a new intact skin antiseptic formulation. <i>American Journal of Infection Control</i> , 2003 , 31, 117-23	3.8	7
58	Comparison of levels of HIV-1 resistance to protease inhibitors by recombinant versus conventional virus phenotypic assay and two genotypic interpretation procedures in treatment-naive and HAART-experienced HIV-infected patients. <i>Journal of Antimicrobial Chemotherapy</i> , 2003 , 51, 135-9	5.1	9
57	Evolutionary characteristics of HIV type 1 variants resistant to protease inhibitors in the absence of drug-selective pressure. <i>AIDS Research and Human Retroviruses</i> , 2003 , 19, 1151-3	1.6	15
56	Processivity and drug-dependence of HIV-1 protease: determinants of viral fitness in variants resistant to protease inhibitors. <i>Aids</i> , 2003 , 17, 663-71	3.5	9
55	Long-term survival and virus production in human primary macrophages infected by human immunodeficiency virus. <i>Journal of Medical Virology</i> , 2002 , 68, 479-88	19.7	86
54	Diverging effects of human recombinant anti-hepatitis C virus (HCV) antibody fragments derived from a single patient on the infectivity of a vesicular stomatitis virus/HCV pseudotype. <i>Journal of Virology</i> , 2002 , 76, 11775-9	6.6	27
53	Reduction of HIV-1 viral load in saliva by indinavir-containing antiretroviral regimen. <i>Aids</i> , 2002 , 16, 503-4	3.5	2

52	Molecular epidemiology of TT virus in Italy and phylogenesis of viral isolates from subjects at different risk for parenteral exposure. <i>Journal of Medical Virology</i> , 2001 , 63, 76-84	19.7	10
51	Inhibition of R5X4 dualtropic HIV-1 primary isolates by single chemokine co-receptor ligands. <i>Virology</i> , 2001 , 280, 253-61	3.6	18
50	Nonneutralizing human antibody fragments against hepatitis C virus E2 glycoprotein modulate neutralization of binding activity of human recombinant Fabs. <i>Virology</i> , 2001 , 288, 29-35	3.6	35
49	Identification of six putative novel human papillomaviruses (HPV) and characterization of candidate HPV type 87. <i>Journal of Virology</i> , 2001 , 75, 11913-9	6.6	21
48	Mapping B-cell epitopes of hepatitis C virus E2 glycoprotein using human monoclonal antibodies from phage display libraries. <i>Journal of Virology</i> , 2001 , 75, 9986-90	6.6	43
47	Transmission of hepatitis C virus in a gynecological surgery setting. <i>Journal of Clinical Microbiology</i> , 2001 , 39, 2860-3	9.7	48
46	Lamivudine treatment failure in preventing fatal outcome of de novo severe acute hepatitis B in patients with haematological diseases. <i>Journal of Hepatology</i> , 2001 , 35, 823-6	13.4	17
45	Molecular profile of a human monoclonal antibody Fab fragment specific for Epstein-Barr virus gp350/220 antigen. <i>Human Immunology</i> , 2001 , 62, 362-7	2.3	5
44	Quantitative evaluation of the recombinant HIV-1 phenotype to protease inhibitors by a single-step strategy. <i>Aids</i> , 2000 , 14, 1101-10	3.5	9
43	Dominant role of host selective pressure in driving hepatitis C virus evolution in perinatal infection. <i>Journal of Virology</i> , 2000 , 74, 4327-34	6.6	52
42	Quantitative molecular analysis of virus expression and replication. <i>Journal of Clinical Microbiology</i> , 2000 , 38, 2030-6	9.7	30
41	Molecular epidemiology of an outbreak of fulminant hepatitis B. <i>Journal of Clinical Microbiology</i> , 2000 , 38, 2975-81	9.7	34
40	Identification of two distinct subsets of long-term nonprogressors with divergent viral activity by stromal-derived factor 1 chemokine gene polymorphism analysis. <i>Journal of Infectious Diseases</i> , 1999 , 180, 285-9	7	26
39	Hepatic stellate cell activation and liver fibrosis are associated with necroinflammatory injury and Th1-like response in chronic hepatitis C. <i>Liver International</i> , 1999 , 19, 212-9	7.9	59
38	Defective nef alleles in a cohort of hemophiliacs with progressing and nonprogressing HIV-1 infection. <i>Virology</i> , 1999 , 259, 349-68	3.6	52
37	Prophylaxis of hepatitis C with intramuscular immunoglobulin: clinical and economic appraisal. <i>BioDrugs</i> , 1999 , 12, 291-300	7.9	3
36	Effect of phenolic and chlorine disinfectants on hepatitis C virus binding and infectivity. <i>American Journal of Infection Control</i> , 1999 , 27, 236-9	3.8	15
35	Dynamics of hepatitis C viremia after plasma exchange. <i>Journal of Hepatology</i> , 1999 , 31, 389-93	13.4	22

34	Host-specific modulation of the selective constraints driving human immunodeficiency virus type 1 env gene evolution. <i>Journal of Virology</i> , 1999 , 73, 3764-77	6.6	31
33	A vector for the expression of recombinant monoclonal Fab fragments in bacteria. <i>Journal of Immunological Methods</i> , 1998 , 217, 195-9	2.5	16
32	Dissection of human humoral immune response against hepatitis C virus E2 glycoprotein by repertoire cloning and generation of recombinant Fab fragments. <i>Hepatology</i> , 1998 , 28, 810-4	11.2	49
31	Are HLA class II and immunoglobulin constant region genes involved in the pathogenesis of mixed cryoglobulinemia type II after hepatitis C virus infection?. <i>Journal of Hepatology</i> , 1998 , 29, 36-44	13.4	26
30	Rare mutations in a domain crucial for V3-loop structure prevail in replicating HIV from long-term non-progressors. <i>Aids</i> , 1998 , 12, 985-997	3.5	22
29	Evolution of hypervariable region 1 of hepatitis C virus in primary infection. <i>Journal of Virology</i> , 1998 , 72, 6271-6	6.6	66
28	Dynamic features of human immunodeficiency virus type 1 (HIV-1) viremia: kinetics of cell-free HIV-1 RNA after therapeutic plasma exchange. <i>Journal of Infectious Diseases</i> , 1997 , 176, 801-4	7	8
27	Selected nucleotide sequence of the pol gene of the monocytotropic strain HIV type 1 BaL. <i>AIDS Research and Human Retroviruses</i> , 1997 , 13, 629-32	1.6	14
26	Homozygous delta 32 deletion of the CCR-5 chemokine receptor gene in an HIV-1-infected patient. <i>Aids</i> , 1997 , 11, F67-71	3.5	91
25	Quantitative liver parameters of HCV infection: relation to HCV genotypes, viremia and response to interferon treatment. <i>Journal of Hepatology</i> , 1997 , 26, 779-86	13.4	22
24	Clinical implications of GBV-C/HGV infection in patients with "HCV-related" chronic hepatitis. <i>Journal of Hepatology</i> , 1997 , 26, 1165-72	13.4	39
23	Low hepatitis C viremia levels in patients with anti-liver/kidney microsomal antibody type 1 positive chronic hepatitis. <i>Journal of Hepatology</i> , 1996 , 25, 433-8	13.4	18
22	Competitive polymerase chain reaction and analysis of viral activity at the molecular level. <i>Genetic Analysis, Techniques and Applications</i> , 1994 , 11, 1-6		15
21	Competitive polymerase chain reaction for quantitating feline immunodeficiency virus load in infected cat tissues. <i>Molecular and Cellular Probes</i> , 1994 , 8, 229-34	3.3	26
20	Clearance of HIV-1 viraemia after seroconversion. <i>Lancet, The</i> , 1993 , 341, 315-6	4.0	13
19	Trans-activation of epidermal growth factor receptor gene by the hepatitis B virus X-gene product. <i>Virology</i> , 1993 , 196, 878-82	3.6	64
18	A novel procedure for quantitative polymerase chain reaction by coamplification of competitive templates. <i>Gene</i> , 1992 , 122, 313-20	3.8	234
17	Sequence analysis of the hepatitis B virus pre-C region in hepatocellular carcinoma [HCC] and nontumoral liver tissues from HCC patients. <i>Virology</i> , 1992 , 188, 890-5	3.6	25

16	Lack of detectable human T-cell lymphotropic virus type I sequences in samples from multiple sclerosis patients. <i>Journal of Medical Virology</i> , 1992 , 36, 155-61	19.7	9
15	Detection of human immunodeficiency virus type 1 genomic RNA in plasma samples by reverse-transcription polymerase chain reaction. <i>Journal of Medical Virology</i> , 1991 , 34, 89-95	19.7	35
14	Levels of pre-S antigens and HBV DNA in sera from high and low viremic HBV carriers. <i>Journal of Medical Virology</i> , 1991 , 35, 273-82	19.7	8
13	A single-step DNA extraction procedure for the detection of serum hepatitis B virus sequences by the polymerase chain reaction. <i>Journal of Virological Methods</i> , 1991 , 32, 245-53	2.6	21
12	Detection of human immunodeficiency virus type 1 transcripts in peripheral blood lymphocytes by the polymerase chain reaction. <i>Journal of Virological Methods</i> , 1991 , 32, 31-9	2.6	19
11	Growth-factor independence of a new differentiated hepatitis B virus DNA-negative human hepatoma cell line. <i>Hepatology</i> , 1990 , 11, 1024-32	11.2	8
10	Expression of high- and low-affinity epidermal growth factor receptors in human hepatoma cell lines. <i>FEBS Letters</i> , 1989 , 249, 297-301	3.8	14
9	Serum-free growth of human hepatoma cells. A review. <i>Advances in Biochemical Engineering/Biotechnology</i> , 1987 , 34, 85-94	1.7	2
8	Differential response of the human hepatoma-derived cell line HA22T/VGH to polypeptide mitogens. <i>FEBS Letters</i> , 1987 , 221, 11-7	3.8	8
7	Modulation of production of hepatitis B surface antigen by a human hepatoma cell line. <i>Journal of Medical Virology</i> , 1984 , 13, 117-23	19.7	5
6	Complement-fixation test for rotavirus detection: comparison and analysis of different methods to reduce anti-complementary activity of some specimens. <i>Journal of Virological Methods</i> , 1982 , 3, 329-35	2.6	1
5	Combined prophylactic and therapeutic use maximizes hydroxychloroquine anti-SARS-CoV-2 effects in vitro		4
4	Heparin inhibits cellular invasion by SARS-CoV-2: structural dependence of the interaction of the surface protein (spike) S1 receptor binding domain with heparin		43
3	Molecular tracing of SARS-CoV-2 in Italy in the first three months of the epidemic		1
2	Poor correlation between antibody titers and neutralizing activity in sera from SARS-CoV-2 infected subjects		6
1	Differential plasmacytoid dendritic cell phenotype and type I Interferon response in asymptomatic and severe COVID-19 infection		4